Arcturus Therapeutics

Arcturus Therapeutics is a global late-stage clinical messenger RNA medicines and vaccines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. We have proprietary technologies, validating partnerships, and an experienced team with deep expertise in delivery and RNA-based therapeutics
Arcturus Therapeutics has built a multicultural team, based in San Diego, CA, USA
We have an exciting COVID-19 vaccine candidate that we hope will make a positive difference in the pandemic
See our team describe what it means for them to help get a vaccine to protect people around the world-no matter where you are from
A
S
L
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/JoePayne_LanguageProficiency_V3_1.mp4?time=1675119645
arabic
(عربى)
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/MaherA_LanguageProficiency_V3_1.mp4?time=1675119645
chinese
(中文)
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/thumbnail_BelleBao.jpg?time=1675119645,https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/BelleBao_LanguageProficiency__V3_1.mp4?time=1675119645
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/thumbnail_HowardYu.jpg?time=1675119645,https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/HowardYu_LanguageProficiency_V3_1.mp4?time=1675119645
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/thumbnail_YurongGuo.jpg?time=1675119645,https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/YurongGuo_LanguageProficiency_V3_1.mp4?time=1675119645
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/thumbnail_XuefengGuo.jpg?time=1675119645,https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/XuefengGuo_LanguageProficiency_V3_1.mp4?time=1675119645
english
(British)
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/MikeHodges_LanguageProficiency_V3_1.mp4?time=1675119645
farsi
(فارسی)
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2022/12/NedaSafarzadeh_LanguageProficiency_V5.mp4?time=1675119645
french
(Français)
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/NadjaEl-mecharrafie_LanguageProficiency_V3_1.mp4?time=1675119645
german
(deutsch)
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/LisaKieweg-Thompson_LanguageProficiency_V3_1.mp4?time=1675119645
hebrew
(עִברִית)
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/thumbnail_NoaScott.jpg?time=1675119645,https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/NoaScott_LanguageProficiency_V3_1.mp4?time=1675119645
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/thumbnail_TamarGrossman.jpg?time=1675119645,https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/TamarGrossman_LanguageProficiency_V3_1.mp4?time=1675119645
hindi
(हिन्दी)
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/PriyaKarmali_LanguageProficiency_V3_1.mp4?time=1675119645
italian
(italiano)
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/thumbnail_CristianoSacchetti.jpg?time=1675119645,https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/CristianoSacchetti_LanguageProficiency_V3_1.mp4?time=1675119645
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/thumbnail_GiulioCattarossi.jpg?time=1675119645,https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/GiulioCattarossi_LanguageProficiency_V3_1.mp4?time=1675119645
Japanese
(日本語)
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/09/Kiyoshi_Tachikawa_v2.mp4?time=1675119645
korean
(한국어)
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/JaeHeonKim_LanguageProficiency_V3_1.mp4?time=1675119645
portuguese
(Português)
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/RamonDiazTrelles_LanguageProficiency_V3_1.mp4?time=1675119645
spanish
(español)
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/CarlosPerezGarcia_LanguageProficiency__V3_1.mp4?time=1675119645
vietnamese
(Tiếng Việt)
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/HannahHuynh_LanguageProficiency_V3_1.mp4?time=1675119645

News & Events

December 19, 2022
Arcturus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 13, 2022
Arcturus Appoints John Markels, Ph.D. to its Board of Directors
December 12, 2022
CSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus Therapeutics
November 9, 2022
Arcturus Therapeutics Announces Third Quarter 2022 Financial Update and Pipeline Progress
November 8, 2022
Arcturus Therapeutics to Present at the Following Investor Conferences in November
November 1, 2022
Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
October 26, 2022
Arcturus Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 9, 2022
September 27, 2022
Arcturus Therapeutics to Attend the Following Investor Conferences
September 1, 2022
Arcturus Therapeutics to Attend the Following Investor Conferences
August 31, 2022
Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of Self-amplifying mRNA Vaccine for Rapid Pandemic Influenza Response
August 18, 2022
Arcturus Reports Durability Data Against Omicron Variants, Including BA.5, at Six-Month Timepoint Following Booster with ARCT-154 COVID-19 Vaccine
August 9, 2022
Arcturus Therapeutics Announces Second Quarter 2022 Financial Update and Pipeline Progress
August 1, 2022
Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022
May 9, 2022
Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress
May 5, 2022
Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial
April 27, 2022
Arcturus Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 9, 2022
April 20, 2022
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
March 25, 2022
Arcturus Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
February 28, 2022
Arcturus Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Update and Pipeline Progress
February 16, 2022
Arcturus Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022

LUNAR® Mechanism of Delivery